Drugmakers are exploring a variety of approaches to treat head and neck cancers, from bispecific antibodies that target both PD-1 and VEGF to antibody-drug conjugates that deliver more targeted attacks.
Head and neck cancer has always been a tough nut to crack. These tumors can suppress immune responses through multiple pathways, meaning blocking one of …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Triple-action therapy drug amivantamab could be given as an injection to help treat recurrent or metastatic cancers
Two of ivonescimab’s biggest competitors are releasing new data in Chicago: pumitamig, from BioNTech and Bristol Myers Squibb;…
The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and…
Una nuova arma contro il glioblastoma, uno dei tumori cerebrali più aggressivi e difficili da trattare, è stata ideata da un team…
Trials that could prevent the disease from returning are to be expanded over the next year in world-first programme
A new study may pave the way for a new generation of cancer treatments by training the body's immune system to more aggressively…
